congenital adrenal hyperplasia

Neurocrine reports positive phase 3 data for hyperplasia drug in children

Neurocrine reports positive phase 3 data for hyperplasia drug in children

Anika Sharma

Just a month after the successful outcome of Neurocrine Biosciences’ phase 3 study for crinecerfont in adults with hyperplasia, the ...

Neurocrine Biosciences, elagolix, hyperplasia, phase 3 trial data, FDA, uterine cancer, congenital adrenal hyperplasia

Neurocrine advances potential blockbuster drug for endometrial hyperplasia after phase 3 success

Anika Sharma

Neurocrine Biosciences is banking on its hyperplasia drug, crinecerfont, which analysts predict could be a blockbuster. The company has been ...